Overview

Molecular Cytogenetics Market is estimated to value over USD 3.24 billion by 2027 end with a CAGR of over 10.9% during the forecast period 2020 to 2027.

The increasing prevalence of genetic disorders, improving healthcare infrastructure, increased adoption of molecular cytogenic products in research and clinical laboratories, pharmaceutical and biotech companies and academic institutes and increased emphasis on targeted treatment of cancer are some of the crucial factors responsible for the growth of the market. The cytogenic analysis earlier focused only on investigating the cellular aspects that detected the genomic aberrations and studying the structure of chromosome in heredity conditions. Currently, cytogenic analysis is being extensively used for applications others than identifying a genome’s chromosomal status, which has enhanced the study of changes in the chromosome involved in the pathogenesis of a disease, the human genome organization in three dimensions.
Human genetics is prominently used for bridging the gap between the provisions of a refined medical service and the applications of findings of genes. Such a broad range of applications shall augment the market growth. Additionally, the rising prevalence of cancer and increased mortality rate annually has substantially helped in the molecular cytogenetics market growth. Such a consistent rise in new cancer cases has increased the necessity for developing novel technologies for a completer understanding of cancer genomically. Some of the recognised cytogenic methods like Comparative Genomic Hybridization and FISH that offer extensive insights about the molecular signatures related to cancer, thereby gaining information on the progression of cancer. Increased pharmacogenomic activities are predicted to substantially influence the proliferation of the market.
However, the reimbursement policies for molecular cytogenetics are unfavourable and these instruments being expensive, the treatments are meant to be expensive as well, thereby negatively affecting the growth of the market.

Molecular Cytogenetics Market

Market Segmentation:

By Technology
•   Fluorescence In-Situ Hybridization
•   Comparative Genomic Hybridization
•   In-Situ Hybridization
•   Karyotyping
•   Banding Techniques
By Product
•   Instruments
•   Kits and Reagents
•   Software
•   Services
•   Consumables/Accessories
By Application
•   Oncology
•   Genetic Disorders
•   Personalized Medicines
•   Others
By End User
•   Pharmaceutical and Biotechnological Companies
•   Clinical and Diagnostic Laboratories
•   Academic Institutes
•   Others
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is fragmented into technology, product, application, end user and region. The technology segment is categorised into fluorescence in-situ hybridization (FISH), comparative genomic hybridization (CGH), in-situ hybridization, karyotyping and bandaging techniques. The CGH technology is anticipated to hold the largest molecular cytogenetics market share owing to the ease of availability, reduced turnaround time, reduced cost and efficient specificity and increased adoption of these technologies across a variety of applications like medicinal development, research activities and diagnostics. Such benefits of FISH and CGH technologies over traditional methods shall proliferate the growth of the market. The product segment is divided into instruments, kits and reagents, software, services and consumables.
The kits and reagents segment is anticipated to lead the market during the forecast period owing to the increased usage of reagents and kits during cytogenetic analysis and the ability to gain reproducible and accurate results in advanced and standard cytogenetic clinical protocols. However, the software and services segments are anticipated to grow at a substantial rate due to the current development in algorithms and solutions for managing and interpreting huge volumes of genomic data. The application segment is categorised into oncology, genetic disorders, personalised medicines and others. The personalised medicine segment is poised to dominate the market owing to it wide range of applications in cytogenomics, cytoproteomics, biomarker discovery and drug development and discovery. The end user segment is divided into pharmaceutical and biotechnological companies, clinical and diagnostic laboratories and others. The clinical and research laboratories segment subjugated the market due to the rising usage of cytogenetic methods for clinical diagnosis.

Regional Analysis:

The North America region is predicted to lead the global market owing to a strong presence of major market players, implementation of an efficient regulatory framework for regulating genetic tests. The Asia Pacific region, however, is anticipated to grow at a significant rate during the forecast period. This is mainly due to the consistent rise in the gross domestic product of nations like India, Japan which shall enhance the buying drive and power of the consumer.

Competitive Landscape:

The prominent market players are Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies, PerkinElmer, Bio-Rad Laboratories, Applied Spectral Imaging, Quest Diagnostics, Roche Diagnostics, Danaher Corporation, Illumina, Oxford Gene Technology.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global molecular cytogenetics market by technology, by product, by application, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com